DHA/EPA

DIETARY_SUPPLEMENT2 trials

Sponsors

National Eye Institute (NEI), Donaghue Medical Research Foundation

Conditions

Age-related Macular DegenerationCataractFrailtyOsteoporosis

Phase 3

Age-Related Eye Disease Study 2 (AREDS2)

CompletedNCT00345176

National Eye Institute (NEI)Age-related Macular Degeneration, Cataract

Start: 2006-09-30End: 2012-10-31Updated: 2015-05-05

Phase 4

Effects of Omega-3 Fatty Acids on Bone and Frailty

Donaghue Medical Research FoundationFrailty, Osteoporosis

Start: 2007-01-31End: 2009-06-30Target: 150Updated: 2009-02-02

Related Papers

Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function

JAMA2015-08-25182 citations

Effect of Long-Chain ω-3 Fatty Acids and Lutein + Zeaxanthin Supplements on Cardiovascular Outcomes

JAMA Internal Medicine2014-03-17119 citations

Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression

JAMA Ophthalmology2014-02-01398 citations

Evaluation of Optimized Digital Fundus Reflex Photographs for Lens Opacities in the Age-Related Eye Disease Study 2: AREDS2 Report 7

Investigative Ophthalmology & Visual Science2013-07-269 citations

Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2).

2013-07-0899 citations

Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.

2013-07-01104 citations

Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

2013-05-01869 citations

Macular pigment imaging in AREDS2 participants: an ancillary study of AREDS2 subjects enrolled at the Moran Eye Center.

2012-09-1432 citations

Brightness, contrast, and color balance of digital versus film retinal images in the age-related eye disease study 2.

2008-04-1749 citations